This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
Immunogen
This CDKL5 (STK9) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 982-1012 amino acids from the C-terminal region of human CDKL5 (STK9).
CDKL5
Reactivity: Human
WB, ELISA, IF (cc), IF (p), IHC (p), IHC (fro), ICC
Host: Rabbit
Polyclonal
unconjugated
Application Notes
WB: 1:1000. IHC-P: 1:10~50
Restrictions
For Research Use only
Format
Liquid
Buffer
Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
Expiry Date
6 months
Target
CDKL5
(Cyclin-Dependent Kinase-Like 5 (CDKL5))
Alternative Name
CDKL5 (STK9)
Background
Defects in STK9, a dual-specificity serine/threonine kinase, are a cause of atypical Rett syndrome. Rett syndrome is an X-linked dominant disease. It is a progressive neurologic developmental disorder and one of the most common causes of mental retardation in females. Patients appear to develop normally until 6 to 18 months of age, then gradually lose speech and purposeful hand movements and develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation, and stereotypic hand movements. After initial regression, the condition stabilizes and patients usually survive into adulthood. Rett syndrome due to CDKL5-associated mutations is characterized by a severe early-onset phenotype and atypical features such as infantile spasms.